Oryzon Genomics S.A. Receivables

Oryzon Genomics S.A. (ORYZF) currently reports a receivables of $2.4M as of June 2026. That compares with $1.8M in the prior-year period — up 33.1% year over year. Use the charts on this page to explore Oryzon Genomics S.A.'s receivables history and peer comparisons.

Oryzon Genomics S.A.'s receivables increased from $1.8M to $2.4M — a 33.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Oryzon Genomics S.A. reported $2.4M in receivables as of June 2026. That compares with $1.8M in the prior-year period — up 33.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $2.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Oryzon Genomics S.A., and consider following ORYZF for alerts when major investors trade the stock.

Oryzon Genomics S.A. is classified in the Healthcare sector. On receivables, it currently shows $2.4M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ORYZF with unrelated industries.